Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $1.81 million for the quarter.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Monday, May 12th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.08. Editas Medicine had a negative return on equity of 139.24% and a negative net margin of 701.06%. The business had revenue of $4.66 million during the quarter, compared to the consensus estimate of $0.79 million. During the same quarter last year, the company earned ($76.00) EPS. On average, analysts expect Editas Medicine to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Editas Medicine Stock Up 4.9%

Shares of NASDAQ EDIT opened at $2.56 on Tuesday. Editas Medicine has a 52 week low of $0.91 and a 52 week high of $4.90. The business has a 50-day simple moving average of $2.42 and a two-hundred day simple moving average of $1.79. The company has a market cap of $214.30 million, a P/E ratio of -0.84 and a beta of 2.19.

Analyst Ratings Changes

EDIT has been the subject of several analyst reports. Robert W. Baird cut their target price on Editas Medicine from $8.00 to $4.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. HC Wainwright began coverage on Editas Medicine in a research report on Monday, April 28th. They set a “buy” rating and a $3.00 price target for the company. Finally, Cantor Fitzgerald upgraded Editas Medicine from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Editas Medicine has a consensus rating of “Hold” and an average target price of $4.70.

Insider Buying and Selling at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 15,192 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total transaction of $26,130.24. Following the transaction, the chief executive officer directly owned 280,282 shares of the company’s stock, valued at approximately $482,085.04. This trade represents a 5.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 21,485 shares of company stock worth $40,897. Company insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Editas Medicine

A hedge fund recently raised its stake in Editas Medicine stock. Acadian Asset Management LLC lifted its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 288.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 752,162 shares of the company’s stock after buying an additional 558,567 shares during the period. Acadian Asset Management LLC owned about 0.90% of Editas Medicine worth $869,000 as of its most recent SEC filing. 71.90% of the stock is currently owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.